Contrasting Pluri (NASDAQ:PLUR) & Biomea Fusion (NASDAQ:BMEA)

Biomea Fusion (NASDAQ:BMEA) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Valuation & Earnings

This table compares Biomea Fusion and Pluri”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$138.43 million	($2.39)	-0.48
Pluri	$1.34 million	23.33	-$22.58 million	($4.92)	-0.63

Pluri has higher revenue and earnings than Biomea Fusion. Pluri is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Biomea Fusion and Pluri, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1	1	7	1	2.80
Pluri	1	0	1	0	2.00

Biomea Fusion presently has a consensus target price of $8.78, indicating a potential upside of 669.98%. Pluri has a consensus target price of $12.00, indicating a potential upside of 285.85%. Given Biomea Fusion’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Biomea Fusion is more favorable than Pluri.

Volatility and Risk

Biomea Fusion has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Insider & Institutional Ownership

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 18.4% of Biomea Fusion shares are held by insiders. Comparatively, 25.9% of Pluri shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Biomea Fusion and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-310.15%	-145.38%
Pluri	-1,890.59%	N/A	-99.68%

Summary

Biomea Fusion beats Pluri on 8 of the 14 factors compared between the two stocks.

About Biomea Fusion

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.